Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akcea Therapeutics, Inc.    AKCA

AKCEA THERAPEUTICS, INC.

(AKCA)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Monteverde & Associates PC Announces an Investigation of Akcea Therapeutics, Inc. - AKCA

09/01/2020 | 05:06pm EST

NEW YORK, Sept. 1, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Akcea Therapeutics, Inc. ("Akcea" or the "Company") (Nasdaq: AKCA) relating to its sale to Ionis Pharmaceuticals, Inc. Under the terms of the agreement, Akcea shareholders will receive $18.15 in cash for each share of Akcea common stock owned.

The investigation focuses on whether Akcea Therapeutics, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process and 2) whether and by how much this proposed transaction undervalues the Company.

Click here for more information: https://www.monteverdelaw.com/case/akcea-therapeutics-inc. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.  Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field.  He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer.  Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019).  Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

If you own stock in Akcea Therapeutics, Inc. and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341
Cell: (646) 522-4840

Attorney Advertising. (C) 2020 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/investor-alert-monteverde--associates-pc-announces-an-investigation-of-akcea-therapeutics-inc--akca-301122443.html

SOURCE Monteverde & Associates PC


© PRNewswire 2020
All news about AKCEA THERAPEUTICS, INC.
11/10IONIS PHARMACEUTICALS : Akcea Therapeutics - WAYLIVRA, the first and only therap..
AQ
11/09IONIS PHARMACEUTICALS : and Akcea Recognize FCS Awareness Day with Global Commun..
AQ
11/04IONIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
11/04Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study ..
AQ
11/02IONIS PHARMACEUTICALS : and Akcea win prestigious Prix Galien Award for TEGSEDI ..
AQ
10/13IONIS PHARMACEUTICALS : completes acquisition of Akcea Therapeutics
AQ
10/13AKCEA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Notice of..
AQ
10/13IONIS PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, ..
AQ
10/12AKCEA THERAPEUTICS : Ionis Pharmaceuticals completes acquisition of Akcea Therap..
PR
09/18AKCEA THERAPEUTICS : WAYLIVRA▼® (volanesorsen), the First and Only Therapy..
BU
More news